U.S.C. homeSearch U.S. Code
U.S. CodeTitle 21Chapter 9— Federal Food, Drug, And Cosmetic ActSubchapter IX— Tobacco Products

21 U.S.C. § 387l (2026)

Judicial review

Edition and currency
U.S. Code current through Pub. L. 119-102 (OLRC release point). The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTU.S. Code current through Pub. L. 119-102 (OLRC release point) ACTIVE · 21 IN 5Y cited 2020–2026 22citing cases
At a glance

Courts have cited this section in 22 opinions since 2020, 21 of them in the last five years. The most litigated part is subsection (b) (12 cases).

(a) Right to review(1) In generalNot later than 30 days after—(A) the promulgation of a regulation under section 387g of this title establishing, amending, or revoking a tobacco product standard; or(B) a denial of an application under section 387j(c) of this title,any person adversely affected by such regulation or denial may file a petition for judicial review of such regulation or denial with the United States Court of Appeals for the District of Columbia or for the circuit in which such person resides or has their principal place of business.(2) Requirements(A) Copy of petition

A copy of the petition filed under paragraph (1) shall be transmitted by the clerk of the court involved to the Secretary.

(B) Record of proceedingsOn receipt of a petition under subparagraph (A), the Secretary shall file in the court in which such petition was filed—(i) the record of the proceedings on which the regulation or order was based; and(ii) a statement of the reasons for the issuance of such a regulation or order.(C) Definition of recordIn this section, the term “record” means—(i) all notices and other matter published in the Federal Register with respect to the regulation or order reviewed;(ii) all information submitted to the Secretary with respect to such regulation or order;(iii) proceedings of any panel or advisory committee with respect to such regulation or order;(iv) any hearing held with respect to such regulation or order; and(v) any other information identified by the Secretary, in the administrative proceeding held with respect to such regulation or order, as being relevant to such regulation or order.
(b) Standard of review

Upon the filing of the petition under subsection (a) for judicial review of a regulation or order, the court shall have jurisdiction to review the regulation or order in accordance with chapter 7 of title 5 and to grant appropriate relief, including interim relief, as provided for in such chapter. A regulation or denial described in subsection (a) shall be reviewed in accordance with section 706(2)(A) of title 5.

(c) Finality of judgment

The judgment of the court affirming or setting aside, in whole or in part, any regulation or order shall be final, subject to review by the Supreme Court of the United States upon certiorari or certification, as provided in section 1254 of title 28.

(d) Other remedies

The remedies provided for in this section shall be in addition to, and not in lieu of, any other remedies provided by law.

(e) Regulations and orders must recite basis in record

To facilitate judicial review, a regulation or order issued under section 387f, 387g, 387h, 387i, 387j, or 387p of this title shall contain a statement of the reasons for the issuance of such regulation or order in the record of the proceedings held in connection with its issuance.

(June 25, 1938, ch. 675, § 912, as added Pub. L. 111–31, div. A, title I, § 101(b)(3), June 22, 2009, 123 Stat. 1819.)
The 20 cases that cite 21 U.S.C. § 387l most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENProhibition Juice Co. v. FDA, 45 F.4th 8 (D.C. Cir. 2022).
cites § 387l 3×subsections: (b) 2× (a)(1)(B)cited by 18 cases
Where it cites § 387l
“And the manufacturers have standing to challenge the FDA’s marketing denial orders, which deny them the authorization the Tobacco Control Act requires before they may lawfully sell their products. The manufacturers assert that the FDA exceeded its statutory authority under the…”
The case’s holding
The Tobacco Control Act expressly instructs the FDA to consider whether a product presents less risk than other tobacco products when determining if marketing is appropriate for public health.
Later courts cite it for
“fda nowhere guaranteed that unspecified other forms of evidence would necessarily be sufficient-only that they might be, so the fda would consider them.” · 2 citing courts
2
REDWages & White Lion Invst v. FDA, 41 F.4th 427 (5th Cir. 2022).
cites § 387l 3×subsections: (b) 2× (a)(1)(B)cited by 10 cases
Vacated by FDA v. Wages and White Lion Investments, LLC (2025): the U.S. Supreme Court's own opinion in this case.
Where it cites § 387l
“Jurisdiction & Standard of Review We have jurisdiction under 21 U.S.C. § 387l(a)(1)(B), which authorizes federal court review of the denial of premarket tobacco product applications in a U.”
3
GREENBreeze Smoke, LLC v. FDA, 18 F.4th 499 (6th Cir. 2021).
cites § 387l 2×subsections: (a)(1)(B) (b)cited by 17 cases
Where it cites § 387l
“Under the Family Smoking Prevention and Tobacco Control Act (“TCA”), however, “any person adversely affected by” the denial of a Premarket Tobacco Product Application may seek judicial review of the denial, 21 U.S.C. § 387l(a)(1)(B), and “the court shall have jurisdiction to…”
The case’s holding
A two-year-old FDA nonbinding guidance does not qualify as longstanding agency policy, so it cannot bind the agency or require acceptance of alternative evidence the FDA finds unsatisfactory.
Later courts cite it for
“it might accept evidence other than long-term studies, if that evidence had sufficient scientific underpinnings.” · 2 citing courts
4
GREENLiquid Labs LLC v. FDA, 52 F.4th 533 (3d Cir. 2022).
cites § 387l 2×subsections: (a)(1)(B) (b)cited by 10 cases
Where it cites § 387l
“4 This Court has jurisdiction pursuant to 21 U.S.C. § 387l(a)(1)(B). 5 We review the FDA’s order denying the PMTAs under the standards set forth in the APA, see 21 U.”
5
GREENLogic Tech. Dev. LLC v. FDA, 84 F.4th 537 (3d Cir. 2023).
cites § 387l 4×subsections: (a)(1)(B) 3× (a)(2)(C)cited by 3 cases
Where it cites § 387l
“§ 1331 and 21 U.S.C. § 387l(a)(1)(B). The Tobacco Control Act directs petitioners to file in the D.”
6
GREENR.J. Reynolds Vapor v. FDA, 65 F.4th 182 (5th Cir. 2023).
cites § 387l 1×subsections: (a)(1)(B)cited by 16 cases
Where it cites § 387l
“5 21 U.S.C. § 387l(a)(1)(B). Also, because it is undisputed that “at least one” petitioner—namely, RJRV—has standing, Article III’s case-or-controversy _____________________ 3 RJRV’s application for Vuse Vibe already spanned over 150,000 pages.”
The case’s holding
An agency cannot penalize a party for good-faith reliance on the agency's prior positions, and must explain unexplained changes in position under the arbitrary-and-capricious standard.
Later courts cite it for
“cannot 'surprise' a party by penalizing it for 'good- faith reliance' on the agency's prior positions.” · 2 citing courts
7
GREENFDA v. R. J. Reynolds Vapor Co., 606 U.S. 226 (2025).
cites § 387l 2×subsections: (a)(1) 2×cited by 5 cases
Where it cites § 387l
“” 21 U. S. C. §387l(a)(1). “Adversely affected” (and its variations like “adversely af- fected or aggrieved”) is a term of art with a “long history in federal administrative law.”
Later courts cite it for
“when congress uses 'one term in one place, and a materially different term in another, the presumption is that the different term denotes a different idea.” · 4 citing courts
8
GREENFontem US, LLC v. FDA, 82 F.4th 1207 (D.C. Cir. 2023).
cites § 387l 2×subsections: (a)(1) 2×cited by 4 cases
Where it cites § 387l
“See 21 U.S.C. § 387l(a)(1). On June 6, 2022, Fontem also submitted an administrative appeal, seeking supervisory review of the order.”
Later courts cite it for
“rested entirely on the finding that fontem had not sufficiently demonstrated that permitting its products to be marked would be 'appropriate for the protection of the public health.” · 2 citing courts
9
GREENAvail Vapor, LLC v. FDA, 55 F.4th 409 (4th Cir. 2022).
cites § 387l 1×subsections: (b)cited by 10 cases
The case’s holding
The Tobacco Control Act requires the FDA to conduct a comparative inquiry weighing a new tobacco product's risks against its benefits before authorizing its marketing.
Later courts cite it for
“the act explicitly contemplates that the fda must embark on a comparative inquiry before allowing any marketing of a new tobacco product.” · 2 citing courts
10
GREENMoose Jooce v. FDA, 981 F.3d 26 (D.C. Cir. 2020).
cites § 387l 1×cited by 8 cases
Where it cites § 387l
“137, 147 (1993); 21 U.S.C. § 387l (2018). B. Notwithstanding Commissioner Gottlieb’s effective ratification, appellants contend that Appointments Clause violations are per se harmful, not curable by ratification, and so the court should consider the merits of their challenge to…”
cites § 387l 1×subsections: (b)cited by 7 cases
Later courts cite it for
“under the prejudicial error rule, a court will not disturb an agency's decision if it determines that the outcome of the agency action would be the same absent agency error.” · 2 citing courts
12
GREENBidi Vapor LLC v. U.S. Food & Drug Admin., 134 F.4th 1282 (11th Cir. 2025).
cites § 387l 2×subsections: (a) (b)cited by 1 case
Where it cites § 387l
“” This timely appeal followed, when Bidi Vapor filed its Peti- tion for Review on January 26, 2024 pursuant to 21 U.S.C. § 387l(a). On February 2, 2024, Bidi Vapor moved for a stay pending appeal, which this Court denied on February 16.”
13
GREENGripum LLC v. FDA, 47 F.4th 553 (7th Cir. 2022).
cites § 387l 3×subsections: (a)(1)(B) 2× (b)cited by 0 cases
Where it cites § 387l
“On October 8, 2021, Gripum timely filed its petition for re- view of the denial order pursuant to 21 U.S.C. § 387l(a)(1)(B). Seeking emergency relief from this court, Gripum filed a mo- tion for a stay pending review on October 17, 2021.”
14
NO FLAGNude Nicotine Inc. v. Fda, No. 21-71321 (9th Cir. July 7, 2023).
cites § 387l 3×subsections: (a) (a)(1)(B) (b)cited by 0 cases
Where it cites § 387l
“See 21 U.S.C. § 387l(a). II “Under the Tobacco Control Act’s judicial review provision, a party subject to a marketing denial order may petition for review either in [the D.”
15
GREENSWT Global Supply, Inc. v. U.S. Food & Drug Admin., 139 F.4th 957 (8th Cir. 2025).
cites § 387l 1×subsections: (a)(1)cited by 0 cases
Where it cites § 387l
“Food and Drug Administration (FDA) denied market authorization for SWT Global’s menthol-flavored ENDS products, and SWT Global seeks our review under 21 U.S.C. § 387l(a)(1). In light of the Supreme Court’s recent decision in Food & Drug Administration v.”
16
NO FLAGR.J. Reynolds v. FDA, No. 23-60128 (5th Cir. Mar. 23, 2023).
cites § 387l 1×subsections: (a)(1)(B)cited by 0 cases
Where it cites § 387l
“5 21 U.S.C. § 387l(a)(1)(B). Also, because it is undisputed that “at least one” petitioner—namely, RJRV—has standing, Article III’s case-or-controversy _____________________ 3 RJRV’s application for Vuse Vibe already spanned over 150,000 pages.”
17
NO FLAGWages & White Lion Invest v. FDA, No. 21-60800 (5th Cir. Jan. 3, 2024).
cites § 387l 1×subsections: (b)cited by 0 cases
Summary
No passage or summary on file for this case yet.
18
NO FLAGElec. Clouds v. FDA, 94 F.4th 950 (10th Cir. 2024).
cites § 387l 1×subsections: (b)cited by 0 cases
Where it cites § 387l
“But even if an error had taken place, it would have been harmless because the FDA would have regarded the marketing plans as deficient for reasons already stated.”
19
NO FLAGShenzhen Youme v. FDA, No. 24-60060 (5th Cir. Aug. 6, 2025).
cites § 387l 1×subsections: (a)(1)cited by 0 cases
Where it cites § 387l
“” 21 U.S.C. § 387l(a)(1). FDA contends that because Youme is a Chinese corporation with no connection to this circuit, it was required to file its petition in the D.”
20
NO FLAGShenzhen IVPS Tech v. FDA, No. 24-60032 (5th Cir. Aug. 6, 2025).
cites § 387l 1×subsections: (a)(1)(B)cited by 0 cases
Where it cites § 387l
“JURISDICTION Under 21 U.S.C. § 387l(a)(1)(B) “any person adversely affected by” the denial of an application filed pursuant to 21 U.”

Show all 22 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
202020232026

One bar per year. Tallest: 6 cases in 2023. 2026 is a partial year. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
5th Cir.7D.C. Cir.33rd Cir.29th Cir.210th Cir.111th Cir.12d Cir.14th Cir.1

The 8 courts with the most citing cases, of 12 courts in all.

By subsection
(a)2 cases
Bidi Vapor LLC v. U.S. Food & Drug Admin., 134 F.4th 1282 (11th Cir. 2025).“” This timely appeal followed, when Bidi Vapor filed its Peti- tion for Review on January 26, 2024 pursuant to 21 U.S.C. § 387l(a). On February 2, 2024, Bidi Vapor moved for a stay pending appeal, which this Court denied on February 16.”
Nude Nicotine Inc. v. Fda, No. 21-71321 (9th Cir. July 7, 2023).“See 21 U.S.C. § 387l(a). II “Under the Tobacco Control Act’s judicial review provision, a party subject to a marketing denial order may petition for review either in [the D.”
(a)(1)5 cases
FDA v. R. J. Reynolds Vapor Co., 606 U.S. 226 (2025).“” 21 U. S. C. §387l(a)(1). “Adversely affected” (and its variations like “adversely af- fected or aggrieved”) is a term of art with a “long history in federal administrative law.”
Fontem US, LLC v. FDA, 82 F.4th 1207 (D.C. Cir. 2023).“See 21 U.S.C. § 387l(a)(1). On June 6, 2022, Fontem also submitted an administrative appeal, seeking supervisory review of the order.”
SWT Global Supply, Inc. v. U.S. Food & Drug Admin., 139 F.4th 957 (8th Cir. 2025).“Food and Drug Administration (FDA) denied market authorization for SWT Global’s menthol-flavored ENDS products, and SWT Global seeks our review under 21 U.S.C. § 387l(a)(1). In light of the Supreme Court’s recent decision in Food & Drug Administration v.”
Shenzhen Youme v. FDA, No. 24-60060 (5th Cir. Aug. 6, 2025).“” 21 U.S.C. § 387l(a)(1). FDA contends that because Youme is a Chinese corporation with no connection to this circuit, it was required to file its petition in the D.”
Fumizer, LLC v. United States Food & Drug Admin., No. 25-5366 (9th Cir. June 24, 2026).
(a)(1)(B)10 cases
Prohibition Juice Co. v. FDA, 45 F.4th 8 (D.C. Cir. 2022).“And the manufacturers have standing to challenge the FDA’s marketing denial orders, which deny them the authorization the Tobacco Control Act requires before they may lawfully sell their products. The manufacturers assert that the FDA exceeded its statutory authority under the…”
Breeze Smoke, LLC v. FDA, 18 F.4th 499 (6th Cir. 2021).“Under the Family Smoking Prevention and Tobacco Control Act (“TCA”), however, “any person adversely affected by” the denial of a Premarket Tobacco Product Application may seek judicial review of the denial, 21 U.S.C. § 387l(a)(1)(B), and “the court shall have jurisdiction to…”
R.J. Reynolds Vapor v. FDA, 65 F.4th 182 (5th Cir. 2023).“5 21 U.S.C. § 387l(a)(1)(B). Also, because it is undisputed that “at least one” petitioner—namely, RJRV—has standing, Article III’s case-or-controversy _____________________ 3 RJRV’s application for Vuse Vibe already spanned over 150,000 pages.”
Logic Tech. Dev. LLC v. FDA, 84 F.4th 537 (3d Cir. 2023).“§ 1331 and 21 U.S.C. § 387l(a)(1)(B). The Tobacco Control Act directs petitioners to file in the D.”
Wages & White Lion Invst v. FDA, 41 F.4th 427 (5th Cir. 2022).“Jurisdiction & Standard of Review We have jurisdiction under 21 U.S.C. § 387l(a)(1)(B), which authorizes federal court review of the denial of premarket tobacco product applications in a U.”
Showing the top 5 of 10. More in the list view →
(a)(2)(C)1 case
Logic Tech. Dev. LLC v. FDA, 84 F.4th 537 (3d Cir. 2023).
(b)12 cases
Prohibition Juice Co. v. FDA, 45 F.4th 8 (D.C. Cir. 2022).
Wages & White Lion Invst v. FDA, 41 F.4th 427 (5th Cir. 2022).
Breeze Smoke, LLC v. FDA, 18 F.4th 499 (6th Cir. 2021).
Liquid Labs LLC v. FDA, 52 F.4th 533 (3d Cir. 2022).“4 This Court has jurisdiction pursuant to 21 U.S.C. § 387l(a)(1)(B). 5 We review the FDA’s order denying the PMTAs under the standards set forth in the APA, see 21 U.”
Avail Vapor, LLC v. FDA, 55 F.4th 409 (4th Cir. 2022).
Showing the top 5 of 12. More in the list view →

Show all 22 citing cases (list view) →

Enactment and amendments
(June 25, 1938, ch. 675, § 912, as added Pub. L. 111–31, div. A, title I, § 101(b)(3), June 22, 2009, 123 Stat. 1819.)
Versions

Edition shown: U.S. Code current through Pub. L. 119-102 (OLRC release point). Syfert holds no earlier or later version of this section.

U.S.C. Home  |  Search U.S. Code  |  Search cases for this section  |  syfert.com